AC Immune (ACIU) Projected to Post Earnings on Tuesday

AC Immune (NASDAQ:ACIU) will likely be posting its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect AC Immune to post earnings of ($0.23) per share and revenue of $0.8060 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 14, 2025 at 11:30 AM ET.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). The business had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Stock Performance

NASDAQ ACIU opened at $3.38 on Monday. The stock has a market cap of $339.39 million, a PE ratio of -5.83 and a beta of 1.56. AC Immune has a twelve month low of $1.43 and a twelve month high of $4.00. The stock has a fifty day simple moving average of $2.81 and a 200-day simple moving average of $2.24.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Zacks Research upgraded AC Immune from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 9th. Weiss Ratings restated a “sell (d-)” rating on shares of AC Immune in a report on Wednesday, October 8th. Finally, BTIG Research restated a “buy” rating and set a $8.00 target price on shares of AC Immune in a report on Monday, September 8th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, AC Immune presently has an average rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On AC Immune

An institutional investor recently bought a new position in AC Immune stock. Sei Investments Co. acquired a new stake in AC Immune (NASDAQ:ACIU) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 24,897 shares of the company’s stock, valued at approximately $51,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.